Joseph G. Jurcic, MD
- Department of Medicine
Division of Hematology/Oncology
Joseph G. Jurcic, MD, is Assistant Professor of Medicine at CUMC and Director of the Hematologic Malignancies Section of the Hematology/Oncology Division. He is a hematologist/oncologist focusing on the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome. His research interests include acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy for leukemia, development of novel small molecule inhibitors for leukemia and molecular monitoring of minimal residual disease.
He is the author or coauthor of more than 75 articles and book chapters, has been the principal investigator on more than 20 clinical trials, and reguarly lectures at national and international meetings. He has been recognized by Castle Connolly in "America's Top Doctors", "Top Doctors: New York Metro Area", and "America's Top Doctors for Cancer". He received his medical degree from the University of Pennsylvania and completed his fellowship in Hematology-Oncology at Memorial Sloan-Kettering Cancer Center.
Honors and Awards
Castle Connolly America's Top Doctors
Castle Connolly Top Doctors: New York Metro Area
Castle Connolly America's Top Doctors for Cancer
Best Doctors in America
Louis and Allston Boyer Young Investigator Award for Distinguished Achievement in Biomedical Research, 2001
World Radioimmunoconjugate Summit, Washington, DC, 2013
MD Anderson Cancer Center Hematology Grand Rounds, Houston TX, 2013
2nd World Congress on Generators and Novel Radiopharmaceuticals, Molecular Imaging, Targeted Radionuclide Therapy, and Dosimetry, Chandigarh, India, 2013
8th International Symposium on Targeted Alpha Therapy, Oak Ridge, TN, 2013
Joseph G. Jurcic, MD
is accepting new patients.
Call (212) 305-5098 for appointments.
One of America's Top Doctors.
Rated One of New York Magazine's
- Internal Medicine
- Medical Oncology
Areas of Expertise
- Acute Leukemia
- Acute Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Aplastic Anemia
- Chronic Leukemia
- Chronic Lymphocytic Leukemia
- CMML (Chronic Myelomonocytic Leukemia)
- Chronic Myelogenous Leukemia
- Essential Thrombocythemia
- Hairy Cell Leukemia
- Hematologic Malignancy
- Hemolytic Anemia
- Immune Thrombocytopenia
- Large Granular Lymphocytic Leukemia
- Lymphoblastic Leukemia
- Myelodysplastic Syndrome
- Myeloproliferative Disease
- Polycythemia Vera
- Waldenstrom's Macroglobulinemia
Herbert Irving Pavilion161 Fort Washington Avenue
New York, NY 10032
- (646) 317-5077
- For new and current patient
appointments, call: (212) 305-5098
Insurance ProgramsPlease contact the provider’s office directly to verify that your particular insurance is accepted.
- Aetna [HMO, Medicare, NY Signature, POS, PPO, Signature Administrators, Student Health]
- Affinity [Essential (Exchange), Medicaid, Medicare]
- CIGNA [Great West, HMO, POS, PPO]
- Empire Blue Cross Blue Shield [Blue Priority, Child Health Plus, EPO, HMO, Medicare (Mediblue), Pathway (Exchange), POS, PPO]
- Fidelis Care [Child/Family Health Plus, Medicaid, Medicare]
- Health First [Child/Family Health Plus, Medicaid, Medicare]
- Health Insurance Plan of NY (HIP) [ConnectiCare, EPO, HMO, Medicaid, Medicare, PPO, Select Care (Exchange), Vytra]
- Health Plus - Amerigroup [Medicaid]
- Health Republic - Freelancers (Exchange)
- Local 1199
- Medicaid [NY]
- Oscar (Exchange)
- Oxford Health Plans [Freedom, Liberty, Medicare]
- United Healthcare [Compass (Exchange), HMO, Medicaid (Community Plan), Medicare, POS, PPO]
- VNSNY CHOICE [Select Health]
- Assistant Professor of Medicine at CUMC
Current Administrative Positions
- Director, Hematologic Malignancies Section
Education And Training
- MD, University of Pennsylvania School of Medicine
- University of Pennslyvania School of Medicine
- Internship: Barnes Jewish Hospital
- Residency: Barnes Jewish Hospital
- Fellowship: Memorial Sloan-Kettering Cancer Center
Education & Training
Leukemia Service, Memorial Sloan-Kettering Cancer Center, 1994-2012
Committee/societies Council Memberships
Southwest Oncology Group, Leukemia Committee and Leukemia Committee Working Group
Society of Hematologic Oncology, Education Committee
American Association of Cancer Research
American Society of Clinical Oncology, Scientific Program Committee on Leukemia, Myelodysplasia, and Transplantation
American Society of Hematology
- Department of Medicine
Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP Jr, Miller WH Jr. Prognostic significance of minimal residual disease detection and PML/RAR-a isoform type: Long-term follow-up in acute promyelocytic leukemia. Blood 2001; 98:2651-2656.
Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud ÅM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100:1233-1239.
Aliff TB, Maslak PB, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA. Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97:1025-1032.
Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, Jurcic J, Velez-Garcia E, Seiter K, Scheinberg DA, Levitt D, Wedel N. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 2003; 17:314-318.
Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas K, Finn RD, Larson SM, O’Reilly RJ, Scheinberg DA, Jurcic JG. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant 2003; 32:549-556.
Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O’Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JG, Brown R, Ehmann WC, Schulman P, Frankel SR, Scheinberg D. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005; 23:4110-4116.
Lamanna N, Jurcic JG, Noy A, Maslak PM, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, Golde D, Scheinberg DA, Zelenetz AD, Weiss MA. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high quality responses: Molecular remissions predict for durable complete responses. J Clin Oncol 2009; 27:491-497.
Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson JJ, Wood BL, Feldman EJ, Galili N, Grove LE, Drachman JG, Sievers EL. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymph 2009; 50:1336-1344.
Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss MA, Jurcic J, Frattini MG, Scheinberg DA. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010; 116:171-179.
Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas K, Weiss MA, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential cytarabine alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 2010; 16:5303-5311.
Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM, Tallman MS. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011; 118:1248-1254.
Brentjens R, Riviere I, Park JH, Davila ML, Want X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B cell leukemias. Blood 2011; 118:4817-4828.
Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers LE, Jurcic JG. Randomized, phase 2b study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated AML. Haematologica 2013 98:119-128.
Goldberg JD, Linker A, Kuk D, Ratan R, Jurcic J, Barker JN, Castro-Malaspina HR, Giralt S, Hsu K, Jakubowski AA, Jenq R, Koehne G, Papadopoulos EB, van den Brink MRM, Young JW, Boulad F, Kernan NA, O’Reilly RJ, Yahalom J, Heller G, Perales M-A. T-cell depleted stem-cell transplantation for adults with high-risk acute lymphocytic leukemia in 1st complete remission: long-term survival with a decreased risk of graft-versus-host disease. Biol Blood Marrow Transplant 2013; 19:208-213.
Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 20 March 2013; 5(177):177ra38.
For a complete list of publications, please visit PubMed.gov